Evidence in favour
- Participation spans 6 named insiders rather than one filing source.
Company insider dossier
Aligos Therapeutics Inc insider intelligence
ALGS filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
50/100
No directional read
30/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 25 Jun 2026
Investment committee read
No directional read
The tape contains filings, but none provide enough priced common-share evidence for a directional classification.
Evidence is contextualDecision risks
- Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Mar 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 6.91 USD
- One-week move
- +3.6%
- Four-week move
- +63.4%
- Fair-value gap
- -47.5%
- Trend signal
- Inactive
- Relative strength
- -20.0
Directional balance
Controlled event mix
0%acquisition
- Acquisition events
- 0
- Disposal events
- 0
- Net value
- $0
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
015 Jun
622 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
017 Aug
024 Aug
031 Aug
Named participants
Insider conviction by person
CHAVEZ, MARGARITADirector500 events
HIRTH, PETERDirector500 events
MARTELL, BRIDGET ADirector500 events
NUECHTERLEIN, CAROLEDirector500 events
PRESTON, HEATHERDirector500 events
SCOPA, JAMES PAULDirector500 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable ALGS filing ledger
Showing 1 to 6 of 6.
CHAVEZ, MARGARITADirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
HIRTH, PETERDirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
MARTELL, BRIDGET ADirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
NUECHTERLEIN, CAROLEDirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
PRESTON, HEATHERDirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
SCOPA, JAMES PAULDirector
AcquisitionOptions and derivatives
5860 sharesStock Option (Right to Buy)
Not reportedContext evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.